Cardiol Therapeutics Files 6-K Report
Ticker: CRDL · Form: 6-K · Filed: Apr 1, 2026 · CIK: 0001702123
Sentiment: neutral
Topics: 6-K, foreign-issuer, regulatory-filing
TL;DR
Cardiol Therapeutics filed a 6-K on 4/1/26, standard foreign issuer report.
AI Summary
Cardiol Therapeutics Inc. filed a Form 6-K on April 1, 2026, reporting information as a foreign issuer. The filing includes standard documents like the 6-K form itself and Exhibit 99.1, along with a graphic file. The company's principal business is in Biological Products, excluding diagnostic substances.
Why It Matters
This filing provides routine updates for investors and regulatory bodies regarding Cardiol Therapeutics' status as a foreign issuer, maintaining transparency in its operations.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign issuer and does not contain specific financial or operational news that would indicate a change in risk.
Key Players & Entities
- Cardiol Therapeutics Inc. (company) — Filer
- 0001702123 (company) — CIK Number
- 001-40712 (company) — File Number
- 2836 (company) — SIC Code for Biological Products
FAQ
What type of filing is this?
This is a Form 6-K, a report of a foreign issuer.
When was this filing accepted by the SEC?
The filing was accepted on April 1, 2026.
What is Cardiol Therapeutics Inc.'s CIK number?
Cardiol Therapeutics Inc.'s CIK number is 0001702123.
What is the primary business of Cardiol Therapeutics Inc. according to the SIC code?
The SIC code 2836 indicates the company's business is Biological Products, excluding diagnostic substances.
What documents are included in this filing?
The filing includes the Form 6-K, Exhibit 99.1, and a graphic file.
Filing Stats: 169 words · 1 min read · ~1 pages · Grade level 11.6 · Accepted 2026-04-01 07:29:42
Filing Documents
- form6k.htm (6-K) — 5KB
- exhibit99-1.htm (EX-99.1) — 25KB
- exhibit99-1xu001.jpg (GRAPHIC) — 8KB
- 0001062993-26-001780.txt ( ) — 42KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CARDIOL THERAPEUTICS INC. (Registrant) Date: April 1, 2026 By: /s/ Chris Waddick Chris Waddick Title: Chief Financial Officer